Influence of antiviral therapy with telbivudine on serum soluble complement receptor type 1 in patients with chronic hepatitis B or liver cirrhosis
10.3969/j.issn.1001-5256.2016.06.019
- VernacularTitle:替比夫定治疗对慢性乙型肝炎和肝硬化患者血清可溶性红细胞补体受体1的影响
- Author:
Fang WANG
1
;
Zuohua QUAN
;
Xingkun YANG
Author Information
1. Department of Infectious Diseases, Anning Branch of General Hospital of Lanzhou Military Area Command, Lanzhou 730070, China
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic;
liver cirrhosis;
telbifvdine;
receptors, complement
- From:
Journal of Clinical Hepatology
2016;32(6):1118-1120
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the changes in serum soluble complement receptor type 1 (sCR1) at 3 and 6 months after antiviral therapy with telbivudine in patients with chronic hepatitis B (CHB) or liver cirrhosis and the influence of telbivudine on serum sCR1 level. MethodsA total of 57 patients with HBeAg-positive CHB or liver cirrhosis were enrolled and given the antiviral therapy with telbivudine. Venous blood was collected before treatment and at 3 and 6 months after treatment, and enzyme-linked immunosorbent assay was used to measure serum sCR1 level. The paired t-test was used for comparison within one group. ResultsAt 3 and 6 months after the antiviral treatment with telbivudine, the serum sCR1 level changed significantly compared with corresponding baseline values (t=4.864 and 6.238, both P＜0.05). The patients with CHB or liver cirrhosis showed significant changes in the serum sCR1 level at 3 and 6 months after treatment compared with corresponding baseline values (t=3425,5468,4047,7378 all P＜0.05). The patients with CHB had a lower serum sCR1 level at baseline and at 3 and 6 months after treatment than those with liver cirrhosis, but the serum sCR1 level at each time point showed no significant differences between the two groups (all P＞005). ConclusionIn patients with HBeAg-positive CHB or liver cirrhosis, serum sCR1 level is reduced significantly after antiviral therapy with telbivudine.
